Epidemiological distribution and drug resistance of Aeromonas and Plesiomonas in the intestine infection

doi:10.3969/j.issn.1673-8640.2018.08.009

Abstract

Abstract:

Objective To study the epidemiological distribution and drug resistance of Aeromonas and Plesiomonas in the intestine infection,and to provide a reference for clinical treatment.Methods The epidemiological distribution and drug resistance of Aeromonas（46 isolates） and Plesiomonas（10 isolates） isolated from feces specimens from 2007 to 2016 were analyzed retrospectively.Results A total of 46 isolates of Aeromonas were isolated from feces specimens,accounting for 22.0% and ranking No.3 in all intestinal isolates. There were 27 isolates of Aeromonas hydrophila（58.7%）,followed by Aeromonas sobria（10 isolates,21.7%） and Aeromonas vienna（9 isolates,19.6%）. There were 10 isolates of Plesiomonas,accounting for 4.8% of all intestinal isolates. There were 27 of 56 isolates isolated from Department of Intestine,10 isolates from Department of Gastroenterology and 19 isolates from other departments. The determination rates for males and females were 42.9% and 57.1%,respectively. It was able to isolate Aeromonas and Plesiomonas all the year round,and the highest isolation rate was 71.4% from July to October. Aeromonas had various degrees of drug resistance to most antibiotics. The drug resistance rates to amikacin,gentamycin,ceftazidime,aztreonam,ciprofloxacin,sulfamethoxazole-trimethoprim,piperacillin-tazobactam and cefepime were 2.2%,6.5%,6.5%,4.3%,6.5%,10.7%,19.6% and 6.5%,respectively. The isolates of Aeromonas were sensitive to meropenem,and 2 isolates were intermediate drug resistant to imipenem. Plesiomonas had various degrees of drug resistance to amikacin,gentamycin,ciprofloxacin and sulfamethoxazole-trimethoprim. The drug resistance rates were 10.0%,20.0%,30.0% and 40.0%,respectively,while Plesiomonas were sensitive to ceftazidime,aztreonam,imipenem,meropenem,piperacillin-tazobactam and cefepime.Conclusions The isolation rates of Aeromonas and Plesiomonas are high,and there were different degrees of drug resistance to various antibiotics,such as quinolones,the 3rd generation and the 4th generation cephalosporins,sulfonamides,aminoglycosides and monocyclic beta-lactams. There exists intermediate drug resistance to imipenem.

Key words: Intestine infection, Aeromonas, Plesiomonas, Epidemiology, Drug resistance rate

CLC Number:

R446.5

LI Shirong, JIANG Xiaofei. Epidemiological distribution and drug resistance of Aeromonas and Plesiomonas in the intestine infection[J]. Laboratory Medicine, 2018, 33(8): 707-710.

Figures/Tables 3

References 13

[1]	CORTET B,COTTEN A,BOUTRY N,et al.Percutaneous vertebroplasty in the treatment of osteoporotic vertebral compression fractures:an open prospective study[J]. J Rheumatol,1999,26(10):2222-2228.
[2]	RUSIN P A,ROSE J B,HAAS C N,et al.Risk assessment of opportunistic bacterial pathogens in drinking water[J]. Rev Enriron Contam Toxicol,1997,152:57-83.
[3]	MIYAGI K,HIRAI L,SANO K.Distribution of Aeromonas species in environmental water used in daily life in Okinawa Prefecture, Japan[J]. Environ Health Prev Med,2016,21(5):287-294.
[4]	NOLLA-SALAS J,CODINA-CALERO J,VALLÉS-ANGULO S,et al. Clinical significance and outcome of Aeromonas spp.infections among 204 adult patients[J]. Eur J Clin Microbiol Infect Dis,2017,36(8):1393-1403.
[5]	刘志远,马玉芝,潘健,等. 气单胞菌肠道感染的临床特点和耐药特征分析[J]. 国际检验医学杂志,2014,35(8):971-972.
[6]	张育禾,徐丽萍,潘佶,等. 宁波市感染性腹泻患者致病性弧菌和气单胞菌分布的研究[J]. 浙江预防医学,2013,25(8):26-28.
[7]	曲芬,崔恩博,鲍春梅,等. 气单胞菌的耐药基因研究[J]. 中华医院感染学杂志,2005,15(3):249-252.
[8]	陈懿,徐景野,李平,等. 腹泻病人中类志贺邻单胞菌的检测及药敏分析[J]. 中国卫生检验杂志,2011,21(4):905-906.
[9]	娄美萍. 33例类志贺邻单胞菌肠炎的临床与其菌株的耐药性分析[J]. 中国热带医学,2008,8(5):788-789.
[10]	李刚山,范泉水,张琳,等. 云南战区部队首次检出类志贺邻单胞菌的生物学鉴定[J]. 中国热带医学,2008,8(8):1407-1408.
[11]	王若南,李医,陈晓,等. 急性腹泻患者类志贺邻单胞菌流行及药物敏感性分析[J]. 中国微生态学杂志,2015,27(12):1413-1416.
[12]	MARCHANDIN H,GODREUIL S,DARBAS H,et al.Extended-spectrum beta-lactamase TEM-24 in an Aeromonas clinical strain:acquisition from the prevalent Enterobacter aerogenes clone in France[J]. Antimicrob Agents Chemother,2003,47(12):3994-3995.
[13]	WU C J,WANG H C,CHEN P L,et al.AQU-1,a chromosomal class C β-lactamase,among clinical Aeromonas dhakensisisolates:distribution and clinical significance[J]. Int J Antimicrob Agents,2013,42(5):456-461.

菌种	检出数（株）	构成比（%）
嗜水气单胞菌	27	58.7
温和气单胞菌	10	21.7
维也纳气单胞菌	9	19.6

菌种	检出数（株）	构成比（%）
嗜水气单胞菌	27	58.7
温和气单胞菌	10	21.7
维也纳气单胞菌	9	19.6

[1]	. [J]. Laboratory Medicine, 2023, 38(7): 692-695.
[2]	FANG Yongmei, ZHANG Yan, XU Xueying, ZHONG Feng. Correlation of Staphylococcus aureus drug resistance with drug resistance genes and virulence genes [J]. Laboratory Medicine, 2023, 38(4): 357-361.
[3]	LIU Congcong, LI Jiaping, ZHOU Hongwei. Performance evaluation of 2 mass spectrometry systems in clinical microbial identification [J]. Laboratory Medicine, 2022, 37(11): 1084-1088.
[4]	. [J]. Laboratory Medicine, 2022, 37(10): 952-954.
[5]	LI Renqiang, LUO Junfeng, CHEN Yundi. Establishment and evaluation of α-thalassemia and β-thalassemia mutation determinations using hetero-tail dual-labeled fluorescent probe hydridization [J]. Laboratory Medicine, 2022, 37(10): 955-962.
[6]	BAO Hailin, HUA Hongyan, SUN Hengliang, LIU Hua, JI Shunnian, QIN Chenhao, DU Hong. Rapid identification of carbapenemase producing Enterobacteriaceae phenotypes by modified Carba Np test and mCIM/eCIM test [J]. Laboratory Medicine, 2022, 37(10): 963-968.
[7]	YANG Xi, SONG Wenqi, DONG Fang, MENG Qingying, ZHEN Jinghui, ZHOU Wei. Application of Gram staining and MALDI-TOF MS in the rapid identification of pathogen kinds in children's positive blood culture [J]. Laboratory Medicine, 2022, 37(10): 969-973.
[8]	WANG Lixin, SU Yunfu, WANG Yi. Research progress on the drug resistance mechanism of clinical pathogens to fosfomycin [J]. Laboratory Medicine, 2022, 37(10): 993-997.
[9]	YANG Xiaolan, HU Zengjun, WANG Shengqing, MA Shuxia, ZENG Yongjie, WANG Chenglei. Distribution of some common intestinal bacteria in elderly patients with acute cerebral infarction and its correlation with cognitive function [J]. Laboratory Medicine, 2022, 37(9): 839-843.
[10]	HAO Jiahui, YANG Zehua. Research progress of bacterial integron determination methods [J]. Laboratory Medicine, 2022, 37(9): 887-891.
[11]	LI Kun, ZHANG Guojun. Research progress of carbon quantum dots and graphene quantum dots in sensing field [J]. Laboratory Medicine, 2022, 37(8): 787-792.
[12]	CHEN Hanlu, WU Shenghai. Influence factors of blood culture negative results and progress of pathogen detection in bloodstream infection [J]. Laboratory Medicine, 2022, 37(7): 688-694.
[13]	DU Jinghui, HUANG Zikun, LIU Min, GONG Jingjing, WANG Dan, LIU Jibo, LIU Xu. Rapid determination of minimum inhibitory concentration and cut-off concentration of Mycobacterium tuberculosis by nitrate reductase assay using liquid medium [J]. Laboratory Medicine, 2022, 37(6): 568-576.
[14]	WEN Qinghui, LI Fengying, LI Yanchang, HUANG Jinyin, WANG Fengping. Drug susceptibility of multidrug-resistant ESBL-producing Escherichia coli to antimicrobial agents restored by different concentrations of EDTA [J]. Laboratory Medicine, 2022, 37(3): 205-208.
[15]	CHU Minjun, LI Xiaojuan, HUANG Hailin, LI Jue, MA Mingbiao, DU Tingyi, WANG Haiping. Influence of delayed entry on fastidious bacterium culture in 2 blood culture systems [J]. Laboratory Medicine, 2022, 37(3): 209-212.